Purified Blood Stem Cells may be Better for Transplant

A bone marrow transplant is standard treatment for both lymphoma and leukemia following aggressive chemotherapy or radiation. Normally, the patient receives blood stem cells from the donor’s bone marrow and some mature of their immune cells—the latter added in order to help the recipient fight any potential infections arising from the procedure.



Unfortunately, these immune cells sometimes attack the recipient’s tissue in what’s known as "graft-versus-host" disease, or GVHD.



Consequently researchers are beginning to look at transplanting purified blood stem cells, and not the mixture that includes the immune cells. So far results have only been seen in lab mice, but according to a recent study led by Dr. Judith Shizuru, a hematologist at Stanford School of Medicine, published online at the Proceedings of the National Academy of Sciences, the lymph nodes of the mice that received purified blood stem cells were larger and healthier than those of mice that received the standard mixture.



In fact, the mixture seemed to be inhibiting recovery time in those mice.



Thus the researchers think that purified blood stem cells could be a better alternative for these transplant patients.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap